BARLOCCO, DANIELA
BARLOCCO, DANIELA
Dipartimento di Scienze Farmaceutiche
Special issue “Novel antibacterial agents”
2021 F. Meneghetti, D. Barlocco
New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents
2019 L.R. Chiarelli, M. Mori, G. Beretta, A. Gelain, E. Pini, J.C. Sammartino, G. Stelitano, D. Barlocco, L. Costantino, M. Lapillo, G. Poli, I. Caligiuri, F. Rizzolio, M. Bellinzoni, T. Tuccinardi, S. Villa, F. Meneghetti
Design, synthesis and biological evaluation of novel antitubercular agents targeting the Salycilate Syntase (MbtI).
2018 S. Villa, L.R. Chiarelli, M. Mori, D. Barlocco, A. Gelain, E. Pini, G. Mori, L. Costantino, T. Tuccinardi, F. Meneghetti
An HTS FP assay able to selectively identify STAT3-DBD inhibitors
2018 F. Meneghetti, D. Barlocco
Discovery and development of novel salicylate synthase (MbtI) Furanic inhibitors as antitubercular agents
2018 L.R. Chiarelli, M. Mori, D. Barlocco, G. Beretta, A. Gelain, E. Pini, M. Porcino, G. Mori, G. Stelitano, L. Costantino, M. Lapillo, D. Bonanni, G. Poli, T. Tuccinardi, S. Villa, F. Meneghetti
New Chromane-Based Derivatives as Inhibitors of Mycobacterium tuberculosis Salicylate Synthase (MbtI) : Preliminary Biological Evaluation and Molecular Modeling Studies
2018 E. Pini, G. Poli, T. Tuccinardi, L. Chiarelli, M. Mori, A. Gelain, L. Costantino, S. Villa, F. Meneghetti, D. Barlocco
An in vivo active 1,2,5-oxadiazole Pt(II) complex : a promising anticancer agent endowed with STAT3 inhibitory properties
2017 F. Porta, G. Facchetti, N. Ferri, A. Gelain, F. Meneghetti, S. Villa, D. Barlocco, D. Masciocchi, A. Asai, N. Miyoshi, S. Marchianò, B. Kwon, Y. Jin, V. Gandin, C. Marzano, I. Rimoldi
A field-based disparity analysis of new 1,2,5-oxadiazole derivatives endowed with antiproliferative activity
2017 F. Porta, A. Gelain, D. Barlocco, N. Ferri, S. Marchiano', V. Cappello, L. Basile, S. Guccione, F. Meneghetti, S. Villa
Synthesis of new dithiolethione and methanethiosulfonate systems endowed with pharmaceutical interest
2017 E. Gabriele, F. Porta, G. Facchetti, C. Galli, A. Gelain, F. Meneghetti, I. Rimoldi, S. Romeo, S. Villa, C. Ricci, N. Ferri, A. Asai, D. Barlocco, A. Sparatore
Special Issue: Frontiers in Antimicrobial Drug Discovery and Design
2017 D. Barlocco, F. Meneghetti
An oxadiazole Pt(II) complex with promising in vivo antitumor activity
2016 F. Porta, G. Facchetti, S. Villa, A. Gelain, F. Meneghetti, D. Barlocco, N. Ferri, C. Marzano, V. Gandin, A. Asai, I. Rimoldi
New inhibitors of salicylate synthase (MbtI) from m. tubercolosis: a promising strategy to antitubercular drugs
2016 S. Villa, A. Gelain, D. Barlocco, E. Pini, G. Beretta, M. Mori, L. Costantino, L.R. Chiarelli, M.R. Pasca, D. Bonanni, T. Tuccinardi, F. Meneghetti
Iron acquisition pathways as targets for antitubercular drugs
2016 F. Meneghetti, S. Villa, A. Gelain, D. Barlocco, L. Chiarelli, M. Pasca, L. Costantino
Ten years of medicinal chemistry (2005-2014) in the Journal of Medicinal Chemistry: Country of contributors, topics, and public-private partnerships
2016 L. Costantino, D. Barlocco
Insulina e farmaci ipoglicemizzanti
2015 D. Barlocco, L. Costantino
STAT3 direct inhibitors: from MD77 to AC33
2015 F. Porta, S. Villa, A. Gelain, D. Barlocco, I. Rimoldi, G. Facchetti, N. Ferri, A. Asai
Oxadiazole Pt(II) complexes: promising STAT3 inhibitors in cancer therapy
2015 G. Facchetti, F. Porta, S. Villa, A. Gelain, F. Meneghetti, D. Barlocco, N. Ferri, A. Asai, I. Rimoldi
Ureido-pyridazinone derivatives : insights into the structural and conformational properties for STAT3 inhibition
2015 F. Meneghetti, S. Villa, D. Masciocchi, D. Barlocco, L. Toma, D-C. Han, B-M. Kwon, N. Ogo, A. Asai, L. Legnani, A. Gelain
New perspectives on the development of antiobesity drugs
2015 L. Costantino, D. Barlocco
New Platinum(II) complexes in STAT3 inhibition: a promising tool for anticancer therapy
2015 I. Rimoldi, F. Porta, S. Villa, A. Gelain, F. Meneghetti, D. Barlocco, N. Ferri, A. Asai, G. Facchetti